MBX Biosciences, Inc. Common Stock (MBX) EV/FCF: History & Chart

MBX Biosciences, Inc. Common Stock(MBX)

Biotechnology · Carmel, IN

$56.53-2.01 (-3.43%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

About MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

Carmel, IN

63 employees

mbxbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Steve Hoerter

View full financials

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
MBX Biosciences, Inc. Common Stock (MBX)	$2.69B	N/A	N/A	N/A	N/A
Precigen, Inc. (PGEN)vs ›	$2.69B	N/A	385.60x	385.60x	385.60x
Acadia Healthcare Company, Inc. (ACHC)vs ›	$2.69B	N/A	177.87x	97.15x	140.18x
AtriCure, Inc. (ATRC)vs ›	$2.73B	51.23x	69.55x	89.95x	89.95x
Aveanna Healthcare Holdings Inc. (AVAH)vs ›	$2.67B	25.72x	31.01x	94.23x	120.63x
TransMedics Group, Inc. (TMDX)vs ›	$2.78B	40.16x	54.95x	90.13x	90.13x
Neogen Corporation (NEOG)vs ›	$2.59B	N/A	247.54x	95.89x	78.72x
Beam Therapeutics Inc. (BEAM)vs ›	$2.58B	N/A	44.45x	44.45x	44.45x
NewAmsterdam Pharma Company N.V. (NAMS)vs ›	$2.57B	N/A	N/A	N/A	N/A
Privia Health Group, Inc. (PRVA)vs ›	$2.57B	N/A	22.38x	30.75x	68.64x

NAME

MARKET CAP

EV/FCF RATIO

TTM

MBX Biosciences, Inc. Common Stock (MBX)

$2.69B

N/A

Precigen, Inc. (PGEN)vs ›

$2.69B

N/A

385.60x

Acadia Healthcare Company, Inc. (ACHC)vs ›